We are a pre-clinical biotech company, pioneering a paradigm shift in the modification of the innate immune system to effectively combat severe diseases.
Our patented novel treatment uses ex-vivo stem cells gene-editing technique to minimize the collateral damage caused by the immune system as a result of its activity. By doing so, we expect to attenuate the progression of these diseases significantly.
This approach has already been proven to work in animal models of Alzheimer's Disease, Multiple Sclerosis, cardiovascular diseases, and more.
We focus first on treating Pulmonary Arterial Hypertension (PAH), a rare, devastating cardiovascular disease which, if left untreated, leads to heart failure and death.
There is currently no cure for this disease, and the primary aims of the current treatments are to improve symptoms and increase exercise tolerance.